Recent Developments and Outlook for Alzheimer’s Disease Treatments
In a special report published on December 5, 2025, we had concluded that:
"All over, unfortunately, 2025 did not provide anything very promising for the 55 million Alzheimer's patients and their caregivers".
Jean-Claude Muller
The intention behind that message was to advise patients and caregivers not to anticipate any new treatment options emerging within the subsequent two to three years. Nevertheless, it was acknowledged that substantial research efforts were underway, aiming to discover and develop innovative treatments, new therapeutic modalities, advanced diagnostics, and valuable non-therapeutic strategies.
Current State of the Field: Insights from Paul Healy
A compelling post on LinkedIn, titled “Alzheimer’s & Neurodegeneration: From the First Disease-Modifying Drugs to a New Era of Prevention, Precision & Possibility”, authored by Paul Healy, offers a thorough overview of the present landscape in Alzheimer’s disease research.
Healy notes that Alzheimer’s and other neurodegenerative conditions are now entering a multi-modality era. This means that a variety of approaches are all being explored simultaneously and sometimes combined. The sheer depth and diversity of this research effort is unprecedented. For many years we have been advocating that "efficient Alzheimer's diseases treatments will entail the combinatory use of preventative symptomatic approaches - including non-therapeutic ones - , anti-inflammatory agents and disease modyfing agents. "
“Alzheimer’s and neurodegenerative diseases are entering a multi-modality era, where drugs, diagnostics, devices, immune modulation, gene silencing, neuromodulation, and lifestyle interventions are all being explored in parallel. Not all will succeed. But the depth and diversity of the pipeline itself is new.” — Paul Healy
Further Reading
The full article where Paul Healy makes a comprehensive narrative of the field can be found at:
Paul Healy 💊🧬
Paris, February 6, 2026
This document has been prepared by Jean-Claude Muller and is provided for information purposes only. The information contained herein has been obtained from sources believed to be reliable but is not warranted to be accurate or complete. The views presented are those of the author at the time of writing and are subject to change. Jean-Claude Muller has no obligation to update these opinions or the information presented.
Comments ()